Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by BigDolphinon Mar 15, 2017 2:05pm

135 Views

Post# 25983414

RE:RE:RE:RE:RE:BEAR-Re News Release

bfw wrote:

BearDownAZ wrote: G1945V,

Let me answer your questions in a different way. ASSERT, SUSTAIN, ASSURE, and BETonMACE trials have all been with patients being given RVX-208 (100 mg, twice a day), on top of statin standard of care. In BETonMACE, all patients are on either atorvastatin (Lipitor) or rosuvastatin (Crestor). If and when BETonMACE succeeds in meeting its endpoint(s), this will prove that RVX-208/apabetalone, in combination with rosuvastatin or atorvastatin, reduces time to first occurence of 3-point MACE.

Therefore, I expect that the first approval by European EMA and/or US FDA for RVX-208/apabetalone to be for high-risk cardiovascular disease patients already taking or being recommended to start taking a statin. I don't know for sure, but in my opinion Resverlogix would have to run additional trial(s) in order to market RVX-208/apabetalone for reduction of MACE events on its own w/o recommending/requiring co-administration of statins.

BDAZ

Agree but not sure any of that matters.

Statin intolerant will get put on it off label.

RVX can make a combo pill and take almost all the Rosuvastatin business.

So, it will get approved alone to be used as add on therapy but it won't matter in the end.

It just needs get to market.

FDA needs to get on board with this trial ASAP